Design Therapeutics (DSGN) Expected to Release Earnings on Wednesday

Design Therapeutics (NASDAQ:DSGN) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.38) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02. On average, analysts expect Design Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.63) EPS for the next fiscal year.

Design Therapeutics Stock Performance

NASDAQ:DSGN opened at $10.63 on Wednesday. The company has a market capitalization of $665.25 million, a P/E ratio of -9.01 and a beta of 1.68. The stock’s 50 day moving average price is $12.93 and its 200 day moving average price is $12.10. Design Therapeutics has a 52 week low of $6.16 and a 52 week high of $17.25.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Design Therapeutics in a report on Friday, October 2nd. They set an “overweight” rating and a $26.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.86.

Design Therapeutics Company Profile

Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.

The company’s research has focused on disorders affecting the nervous system, muscles and eyes.